Author

Yelena Broitman

FAVOURABLE FIRST YEAR REMISSION RATES AMONG PATIENTS WITH NEWLY DIAGNOSED CROHN'S DISEASE: DATA FROM A REAL-WORLD PROSPECTIVE INCEPTION COHORT
FAVOURABLE FIRST YEAR REMISSION RATES AMONG PATIENTS WITH NEWLY DIAGNOSED CROHN'S DISEASE: DATA FROM A REAL-WORLD PROSPECTIVE INCEPTION COHORT

Yelena Broitman  et al.

A SIMPLE WEB-BASED TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS USING EXPLAINABLE ARTIFICIAL INTELLIGENCE
A SIMPLE WEB-BASED TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS USING EXPLAINABLE ARTIFICIAL INTELLIGENCE

Yelena Broitman  et al.

MICROBIAL SIGNATURE OF PATIENTS WITH NEWLY DIAGNOSED CROHN’S DISEASE IDENTIFIES PATIENTS WITH COMPLICATED DISEASE COURSE
MICROBIAL SIGNATURE OF PATIENTS WITH NEWLY DIAGNOSED CROHN’S DISEASE IDENTIFIES PATIENTS WITH COMPLICATED DISEASE COURSE

Yelena Broitman  et al.

SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Yelena Broitman  et al.

Item 1 - 4 / 4
1